Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2023

In 2023, Axsome Therapeutics, Inc.'s disclosed short interest ran from 18.27% of shares outstanding on 13 Jan 2023 to 17.80% on 29 Dec 2023, a change of -0.47 percentage points. The year's high was 21.35% on 14 Jul 2023 and its low 15.52% on 31 Oct 2023, averaging 18.05% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.45 days on 31 Aug 2023. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2023

2023 in figures

Start of year
18.27% (13 Jan 2023)
End of year
17.80% (29 Dec 2023)
Change
-0.47 pp
High
21.35% (14 Jul 2023)
Low
15.52% (31 Oct 2023)
Average
18.05%
Highest days to cover
14.45 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

Axsome Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202318.27%6.71
31 Jan 202317.58%9.45
15 Feb 202318.55%7.81
28 Feb 202319.34%8.20results (8-K), 10-K filed
15 Mar 202319.65%8.64
31 Mar 202318.90%11.05
14 Apr 202318.06%9.29
28 Apr 202318.40%11.13
15 May 202317.60%8.64results (8-K), 10-Q filed
31 May 202317.77%11.70
15 Jun 202317.81%9.79
30 Jun 202320.97%6.33
14 Jul 202321.35%10.67
31 Jul 202319.19%11.68
15 Aug 202318.09%9.2310-Q filed, results (8-K)
31 Aug 202317.46%14.45
15 Sep 202317.21%11.78
29 Sep 202315.82%11.80
13 Oct 202316.08%11.56
31 Oct 202315.52%12.15
15 Nov 202316.15%9.2610-Q filed, results (8-K)
30 Nov 202317.86%13.69
15 Dec 202317.66%12.97
29 Dec 202317.80%13.54

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.